DEERFIELD MANAGEMENT CO /NY
Insider CIK 1009258 · STRM 10% owner · AVDL 10% owner · ATRS 10% owner · CBIO 10% owner · LUMO 10% owner · XNPT 10% owner · TLON.OB 10% owner · AUXL 10% owner · ALIM 10% owner · EHTH 10% owner · AERI 10% owner · LIFE 10% owner · XERS 10% owner · VNDA 10% owner · PRTO Director, 10% owner · ZFGN Director, 10% owner · IVTY 10% owner · DRNA 10% owner · TRIV 10% owner · CNST 10% owner · ASPX 10% owner · NEOS 10% owner · SDGR 10% owner · NVTA 10% owner · AAVL 10% owner · CTMX 10% owner · AFIB Director, 10% owner · ANNX 10% owner · GRAY 10% owner · SYRS 10% owner · ACRS 10% owner · MNK 10% owner · GUTS 10% owner · LOXO 10% owner · REPH 10% owner · RGNX 10% owner · STDY 10% owner · NVLS Director, 10% owner · RVMD 10% owner · BOLD 10% owner · SWAV 10% owner · RYTM 10% owner · EDIT 10% owner · AVXS 10% owner · ARVN 10% owner · PBLS 10% owner · FIXX Director, 10% owner · ONCR Director, 10% owner · SPRY 10% owner · BDTX 10% owner · FREQ 10% owner · EWTX 10% owner · DFBH Director, 10% owner · KNSA 10% owner · GBIO 10% owner · PHGE Director, 10% owner · CABA 10% owner · MIRM 10% owner · HOWL 10% owner · NKTX 10% owner · DFPH Director, 10% owner · DFHT Director, 10% owner · TERN 10% owner · PEPG 10% owner · XLO 10% owner · OMIC 10% owner · NUVL Director, 10% owner · DALS Director, 10% owner · BCAX 10% owner · CASM 10% owner · AXGN 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 20,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 20,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 43,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 43,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 2,717,627 | $124.00 | $336.99M | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 2,717,627 | $124.00 | $336.99M | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 15,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 3,789 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 3,789 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 4,147 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 4,147 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 15,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer | 2026-07-15 | 2026-07-17 | 8,299,225 | $124.00 | $1.03B | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer | 2026-07-15 | 2026-07-17 | 8,299,225 | $124.00 | $1.03B | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer | 2026-07-15 | 2026-07-17 | 650,000 | $124.00 | $80.60M | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | U Tender | 2026-07-15 | 2026-07-17 | 5,146 | $124.00 | $638.1K | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer | 2026-07-15 | 2026-07-17 | 3,444 | $124.00 | $427.1K | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | U Tender | 2026-07-15 | 2026-07-17 | 5,146 | $124.00 | $638.1K | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award | 2026-06-16 | 2026-06-18 | 3,444 | — | $0 | 3,444 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion deriv | 2026-06-11 | 2026-06-11 | 246,732 | — | $0 | 0 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion deriv | 2026-06-11 | 2026-06-11 | 246,732 | — | $0 | 0 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion deriv | 2026-06-11 | 2026-06-11 | 464,550 | — | $0 | 0 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion deriv | 2026-06-11 | 2026-06-11 | 464,550 | — | $0 | 0 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion deriv | 2026-06-11 | 2026-06-11 | 143,650 | — | $0 | 0 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion deriv | 2026-06-11 | 2026-06-11 | 166,070 | — | $0 | 0 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion deriv | 2026-06-11 | 2026-06-11 | 166,070 | — | $0 | 0 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion deriv | 2026-06-11 | 2026-06-11 | 143,650 | — | $0 | 0 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion | 2026-06-11 | 2026-06-11 | 149,238 | — | $0 | 272,228 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion | 2026-06-11 | 2026-06-11 | 122,990 | — | $0 | 122,990 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion | 2026-06-11 | 2026-06-11 | 122,990 | — | $0 | 122,990 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion | 2026-06-11 | 2026-06-11 | 149,238 | — | $0 | 272,228 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion | 2026-06-11 | 2026-06-11 | 260,992 | — | $0 | 533,220 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion | 2026-06-11 | 2026-06-11 | 260,992 | — | $0 | 533,220 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion | 2026-06-11 | 2026-06-11 | 407,132 | — | $0 | 940,352 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion | 2026-06-11 | 2026-06-11 | 407,132 | — | $0 | 940,352 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | A Award deriv | 2026-05-19 | 2026-05-20 | 55,150 | — | $0 | 55,150 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2026-02-27 | 2026-03-02 | 1,084,012 | $5.00 | $5.42M | 10,622,957 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2026-02-27 | 2026-03-02 | 831,978 | $5.00 | $4.16M | 8,153,107 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2026-02-27 | 2026-03-02 | 2,000,000 | $5.00 | $10.00M | 6,207,982 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2026-02-27 | 2026-03-02 | 1,084,010 | $5.00 | $5.42M | 10,622,928 | SEC↗ |
| NUVL Nuvalent, Inc. | S Sale | 2025-11-24 | 2025-11-24 | 371,287 | $95.45 | $35.44M | 8,299,225 | SEC↗ |
| NUVL Nuvalent, Inc. | S Sale | 2025-11-24 | 2025-11-24 | 371,287 | $95.45 | $35.44M | 8,299,225 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2025-07-31 | 2025-08-04 | 2,599,932 | $3.20 | $8.32M | 7,321,129 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2025-07-31 | 2025-08-04 | 3,387,539 | $3.20 | $10.84M | 9,538,945 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2025-07-31 | 2025-08-04 | 3,387,529 | $3.20 | $10.84M | 9,538,918 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2025-06-27 | 2025-07-01 | 370,075 | $18.46 | $6.83M | 4,887,254 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2025-06-27 | 2025-07-01 | 370,074 | $18.46 | $6.83M | 4,887,254 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award deriv | 2025-06-18 | 2025-06-20 | 4,147 | — | $0 | 4,147 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award deriv | 2025-06-18 | 2025-06-20 | 4,147 | — | $0 | 4,147 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award | 2025-06-18 | 2025-06-20 | 2,647 | — | $0 | 2,647 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award | 2025-06-18 | 2025-06-20 | 2,647 | — | $0 | 2,647 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | A Award deriv | 2025-05-13 | 2025-05-15 | 19,000 | — | $0 | 19,000 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2025-04-21 | 2025-04-23 | 1,611,864 | — | $0 | 1,611,864 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2025-04-21 | 2025-04-23 | 1,611,864 | — | $0 | 1,611,864 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2025-04-14 | 2025-04-18 | 17,600 | — | $0 | 17,600 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2025-02-27 | 2025-03-03 | 1,258,614 | — | $0 | 1,258,614 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2025-02-27 | 2025-03-03 | 1,258,614 | — | $0 | 1,258,614 | SEC↗ |
| PHGE BiomX Inc. | M Exercise deriv | 2025-02-27 | 2025-03-03 | 1,611,863 | — | $0 | 405,637 | SEC↗ |
| PHGE BiomX Inc. | M Exercise deriv | 2025-02-27 | 2025-03-03 | 1,611,863 | — | $0 | 405,637 | SEC↗ |
| PHGE BiomX Inc. | M Exercise | 2025-02-27 | 2025-03-03 | 353,249 | $0.93 | $328.5K | 1,247,054 | SEC↗ |
| PHGE BiomX Inc. | M Exercise | 2025-02-27 | 2025-03-03 | 353,249 | $0.93 | $328.5K | 1,247,054 | SEC↗ |
| AFIB Acutus Medical, Inc. | D To issuer deriv | 2025-01-27 | 2025-01-28 | 193,002 | — | $0 | 0 | SEC↗ |
| AFIB Acutus Medical, Inc. | D To issuer deriv | 2025-01-27 | 2025-01-28 | 31,116 | — | $0 | 0 | SEC↗ |
| AFIB Acutus Medical, Inc. | D To issuer deriv | 2025-01-27 | 2025-01-28 | 1,889,509 | — | $0 | 0 | SEC↗ |
| AFIB Acutus Medical, Inc. | D To issuer deriv | 2025-01-27 | 2025-01-28 | 209,996 | — | $0 | 0 | SEC↗ |
| AFIB Acutus Medical, Inc. | D To issuer deriv | 2025-01-27 | 2025-01-28 | 1,889,509 | — | $0 | 0 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-12 | 2024-11-13 | 9,554 | $17.77 | $169.8K | 5,257,329 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-12 | 2024-11-13 | 7,854 | $17.16 | $134.8K | 5,266,881 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-12 | 2024-11-13 | 7,853 | $17.16 | $134.8K | 5,266,883 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-12 | 2024-11-13 | 9,553 | $17.77 | $169.8K | 5,257,328 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-11 | 2024-11-13 | 223,632 | $18.15 | $4.06M | 5,274,735 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-11 | 2024-11-13 | 223,632 | $18.15 | $4.06M | 5,274,736 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-11 | 2024-11-13 | 40,596 | $17.45 | $708.4K | 5,498,367 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-11 | 2024-11-13 | 40,596 | $17.45 | $708.4K | 5,498,368 | SEC↗ |
| NUVL Nuvalent, Inc. | S Sale | 2024-10-22 | 2024-10-24 | 1,000,000 | $97.75 | $97.75M | 8,670,512 | SEC↗ |
| NUVL Nuvalent, Inc. | S Sale | 2024-10-22 | 2024-10-24 | 1,000,000 | $97.75 | $97.75M | 8,670,512 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | C Conversion deriv | 2024-09-17 | 2024-09-17 | 7,973,325 | — | $0 | 0 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | C Conversion deriv | 2024-09-17 | 2024-09-17 | 7,973,325 | — | $0 | 0 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | P Buy | 2024-09-17 | 2024-09-17 | 35,000 | $18.00 | $630.0K | 897,587 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | P Buy | 2024-09-17 | 2024-09-17 | 35,000 | $18.00 | $630.0K | 897,587 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | C Conversion | 2024-09-17 | 2024-09-17 | 862,587 | — | $0 | 862,587 | SEC↗ |
| BCAX Bicara Therapeutics Inc. | C Conversion | 2024-09-17 | 2024-09-17 | 862,587 | — | $0 | 862,587 | SEC↗ |
| PHGE BiomX Inc. | M Exercise deriv | 2024-07-15 | 2024-07-17 | 5,883 | — | $0 | 47,957 | SEC↗ |
| PHGE BiomX Inc. | M Exercise deriv | 2024-07-15 | 2024-07-17 | 5,883 | — | $0 | 47,957 | SEC↗ |
| PHGE BiomX Inc. | M Exercise | 2024-07-15 | 2024-07-17 | 5,883,000 | — | $0 | 8,938,049 | SEC↗ |
| PHGE BiomX Inc. | M Exercise | 2024-07-15 | 2024-07-17 | 5,883,000 | — | $0 | 8,938,049 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2024-07-11 | 2024-07-15 | 264,000 | — | $0 | 264,000 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2024-07-09 | 2024-07-11 | 20,175,000 | — | $0 | 20,175,000 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2024-07-09 | 2024-07-11 | 20,175,000 | — | $0 | 20,175,000 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2024-07-09 | 2024-07-11 | 722,175 | — | $0 | 722,175 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2024-07-09 | 2024-07-11 | 722,175 | — | $0 | 722,175 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award deriv | 2024-06-12 | 2024-06-14 | 3,789 | — | $0 | 3,789 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award deriv | 2024-06-12 | 2024-06-14 | 3,789 | — | $0 | 3,789 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award | 2024-06-12 | 2024-06-14 | 2,499 | — | $0 | 2,499 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award | 2024-06-12 | 2024-06-14 | 2,499 | — | $0 | 2,499 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | A Award deriv | 2024-05-29 | 2024-06-03 | 19,000 | — | $0 | 19,000 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2024-03-15 | 2024-03-19 | 13,490 | — | $0 | 13,490 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2024-03-15 | 2024-03-19 | 40,350 | — | $0 | 53,840 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2024-03-15 | 2024-03-19 | 40,350 | — | $0 | 53,840 | SEC↗ |
| PHGE BiomX Inc. | A Award deriv | 2024-03-15 | 2024-03-19 | 13,490 | — | $0 | 13,490 | SEC↗ |
| PHGE BiomX Inc. | A Award | 2024-03-15 | 2024-03-19 | 3,055,049 | — | $0 | 3,055,049 | SEC↗ |
| PHGE BiomX Inc. | A Award | 2024-03-15 | 2024-03-19 | 3,055,049 | — | $0 | 3,055,049 | SEC↗ |
| AHCO AdaptHealth Corp. | S Sale | 2024-03-12 | 2024-03-12 | 114,906 | $10.70 | $1.23M | 11,528,863 | SEC↗ |
| AHCO AdaptHealth Corp. | S Sale | 2024-03-11 | 2024-03-12 | 94,567 | $10.92 | $1.03M | 11,731,809 | SEC↗ |
| AHCO AdaptHealth Corp. | S Sale | 2024-03-11 | 2024-03-12 | 88,040 | $11.13 | $979.9K | 11,643,769 | SEC↗ |
| AHCO AdaptHealth Corp. | S Sale | 2024-03-08 | 2024-03-12 | 4,495 | $11.03 | $49.6K | 11,826,376 | SEC↗ |
| AHCO AdaptHealth Corp. | S Sale | 2024-03-08 | 2024-03-12 | 47,992 | $10.92 | $524.1K | 11,830,871 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2024-02-16 | 2024-02-16 | 1,430,205 | $8.74 | $12.50M | 4,207,982 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2024-02-16 | 2024-02-16 | 1,430,206 | $8.74 | $12.50M | 6,151,389 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2024-02-16 | 2024-02-16 | 1,430,206 | $8.74 | $12.50M | 6,151,406 | SEC↗ |
| GUTS Fractyl Health, Inc. | C Conversion deriv | 2024-02-06 | 2024-02-08 | 1,625,699 | — | $0 | 0 | SEC↗ |
| GUTS Fractyl Health, Inc. | C Conversion deriv | 2024-02-06 | 2024-02-08 | 164,612 | — | $0 | 0 | SEC↗ |
| GUTS Fractyl Health, Inc. | C Conversion | 2024-02-06 | 2024-02-08 | 76,706 | — | $0 | 834,254 | SEC↗ |
| GUTS Fractyl Health, Inc. | C Conversion | 2024-02-06 | 2024-02-08 | 757,548 | — | $0 | 757,548 | SEC↗ |
| CMAX CareMax, Inc. | M Exercise deriv | 2023-11-17 | 2023-11-21 | 12,123 | — | $0 | 0 | SEC↗ |
| CMAX CareMax, Inc. | M Exercise | 2023-11-17 | 2023-11-21 | 12,123 | — | $0 | 12,123 | SEC↗ |
| DALS DA32 Life Science Tech Acq | J Other | 2023-07-28 | 2023-08-01 | 1,600,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award deriv | 2023-06-15 | 2023-06-16 | 15,000 | — | $0 | 15,000 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award deriv | 2023-06-15 | 2023-06-16 | 15,000 | — | $0 | 15,000 | SEC↗ |
| AFIB Acutus Medical, Inc. | A Award deriv | 2023-06-15 | 2023-06-20 | 19,600 | — | $0 | 19,600 | SEC↗ |
| AFIB Acutus Medical, Inc. | A Award | 2023-06-15 | 2023-06-20 | 8,400 | — | $0 | 20,822 | SEC↗ |
| CMAX CareMax, Inc. | A Award deriv | 2023-06-08 | 2023-06-12 | 33,750 | — | $0 | 33,750 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | A Award deriv | 2023-05-09 | 2023-05-11 | 8,300 | — | $0 | 8,300 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-30 | 2022-12-30 | 15,220 | $0.27 | $4.1K | 284,697 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-30 | 2022-12-30 | 61,826 | $0.27 | $16.7K | 1,156,309 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-30 | 2022-12-30 | 61,826 | $0.27 | $16.7K | 1,156,308 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-29 | 2022-12-30 | 63,107 | $0.26 | $16.4K | 1,218,135 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-29 | 2022-12-30 | 63,108 | $0.26 | $16.4K | 1,218,134 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-29 | 2022-12-30 | 15,538 | $0.26 | $4.0K | 299,917 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-28 | 2022-12-30 | 24,757 | $0.25 | $6.2K | 1,281,242 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-28 | 2022-12-30 | 6,096 | $0.25 | $1.5K | 315,455 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-28 | 2022-12-30 | 24,757 | $0.25 | $6.2K | 1,281,242 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-27 | 2022-12-27 | 7,136 | $0.27 | $1.9K | 321,551 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-27 | 2022-12-27 | 28,977 | $0.27 | $7.8K | 1,305,999 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-27 | 2022-12-27 | 28,977 | $0.27 | $7.8K | 1,305,999 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-22 | 2022-12-27 | 3,693 | $0.28 | $1.0K | 1,334,976 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-22 | 2022-12-27 | 3,692 | $0.28 | $1.0K | 1,334,976 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-22 | 2022-12-27 | 909 | $0.28 | $255 | 328,687 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-21 | 2022-12-21 | 6,144 | $0.30 | $1.8K | 1,338,668 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-21 | 2022-12-21 | 6,143 | $0.30 | $1.8K | 1,338,669 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-21 | 2022-12-21 | 1,513 | $0.30 | $454 | 329,596 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-20 | 2022-12-21 | 1,616 | $0.31 | $501 | 331,109 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-20 | 2022-12-21 | 6,562 | $0.31 | $2.0K | 1,344,812 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-20 | 2022-12-21 | 6,562 | $0.31 | $2.0K | 1,344,812 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-19 | 2022-12-21 | 44,394 | $0.29 | $12.9K | 1,351,374 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-19 | 2022-12-21 | 44,394 | $0.29 | $12.9K | 1,351,374 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-19 | 2022-12-21 | 10,930 | $0.29 | $3.2K | 332,725 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-15 | 2022-12-15 | 1,375 | $0.39 | $536 | 1,395,768 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-15 | 2022-12-15 | 339 | $0.39 | $132 | 343,655 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-15 | 2022-12-15 | 1,375 | $0.39 | $536 | 1,395,768 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-14 | 2022-12-15 | 943 | $0.38 | $358 | 343,994 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-14 | 2022-12-15 | 3,829 | $0.38 | $1.5K | 1,397,143 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-14 | 2022-12-15 | 3,828 | $0.38 | $1.5K | 1,397,143 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-13 | 2022-12-15 | 934 | $0.41 | $383 | 1,400,971 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-13 | 2022-12-15 | 933 | $0.41 | $383 | 1,400,972 | SEC↗ |
| ONCR Oncorus, Inc. | S Sale | 2022-12-13 | 2022-12-15 | 230 | $0.41 | $94 | 344,937 | SEC↗ |
| CMAX CareMax, Inc. | A Award deriv | 2022-11-17 | 2022-11-21 | 12,123 | — | $0 | 12,123 | SEC↗ |
| NUVL Nuvalent, Inc. | P Buy | 2022-11-03 | 2022-11-07 | 650,000 | $33.50 | $21.77M | 650,000 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2022-09-16 | 2022-09-20 | 2,777,777 | $3.15 | $8.75M | 2,777,777 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2022-09-16 | 2022-09-20 | 2,777,777 | $3.15 | $8.75M | 4,721,197 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2022-09-16 | 2022-09-20 | 2,777,777 | $3.15 | $8.75M | 4,721,183 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2022-09-16 | 2022-09-20 | 2,777,777 | $3.15 | $8.75M | 4,721,200 | SEC↗ |
| AFIB Acutus Medical, Inc. | A Award deriv | 2022-06-30 | 2022-07-05 | 1,889,509 | — | $0 | 1,889,509 | SEC↗ |
| AFIB Acutus Medical, Inc. | A Award deriv | 2022-06-30 | 2022-07-05 | 1,889,509 | — | $0 | 1,889,509 | SEC↗ |
| AFIB Acutus Medical, Inc. | A Award deriv | 2022-06-16 | 2023-06-20 | 19,600 | — | $0 | 19,600 | SEC↗ |
| AFIB Acutus Medical, Inc. | A Award | 2022-06-16 | 2023-06-20 | 8,400 | — | $0 | 12,422 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award deriv | 2022-06-16 | 2022-06-21 | 20,000 | — | $0 | 20,000 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award deriv | 2022-06-16 | 2022-06-21 | 20,000 | — | $0 | 20,000 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 171 | $25.08 | $4.3K | 1,711,153 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 6,909 | $24.47 | $169.1K | 1,704,244 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 155 | $25.08 | $3.9K | 1,546,433 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 6,243 | $24.47 | $152.8K | 1,540,190 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 11,868 | $25.29 | $300.1K | 1,546,588 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 13,132 | $25.29 | $332.1K | 1,711,324 | SEC↗ |
| PEPG PepGen Inc. | C Conversion deriv | 2022-05-10 | 2022-05-10 | 273,313 | — | $0 | 0 | SEC↗ |
| PEPG PepGen Inc. | C Conversion deriv | 2022-05-10 | 2022-05-10 | 273,313 | — | $0 | 0 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | A Award deriv | 2022-05-10 | 2022-05-11 | 8,300 | — | $0 | 8,300 | SEC↗ |
| PEPG PepGen Inc. | P Buy | 2022-05-10 | 2022-05-10 | 208,333 | $12.00 | $2.50M | 476,813 | SEC↗ |
| PEPG PepGen Inc. | P Buy | 2022-05-10 | 2022-05-10 | 208,333 | $12.00 | $2.50M | 476,813 | SEC↗ |
| PEPG PepGen Inc. | C Conversion | 2022-05-10 | 2022-05-10 | 268,480 | — | $0 | 268,480 | SEC↗ |
| PEPG PepGen Inc. | C Conversion | 2022-05-10 | 2022-05-10 | 268,480 | — | $0 | 268,480 | SEC↗ |
| DFPH Oncology Institute, Inc. | C Conversion deriv | 2021-11-12 | 2021-11-16 | 85,113 | — | $0 | 0 | SEC↗ |
| DFPH Oncology Institute, Inc. | J Other deriv | 2021-11-12 | 2021-11-16 | 625,000 | — | $0 | 625,000 | SEC↗ |
| DFPH Oncology Institute, Inc. | P Buy deriv | 2021-11-12 | 2021-11-16 | 50,000 | $1000.00 | $50.00M | 58,945 | SEC↗ |
| DFPH Oncology Institute, Inc. | P Buy deriv | 2021-11-12 | 2021-11-16 | 50,000 | $1000.00 | $50.00M | 58,945 | SEC↗ |
| DFPH Oncology Institute, Inc. | J Other deriv | 2021-11-12 | 2021-11-16 | 707,960 | — | $0 | 40 | SEC↗ |
| DFPH Oncology Institute, Inc. | J Other deriv | 2021-11-12 | 2021-11-16 | 14,887 | — | $0 | 85,113 | SEC↗ |
| DFPH Oncology Institute, Inc. | C Conversion deriv | 2021-11-12 | 2021-11-16 | 40 | — | $0 | 0 | SEC↗ |
| DFPH Oncology Institute, Inc. | J Other deriv | 2021-11-12 | 2021-11-16 | 3,177,543 | — | $0 | 3,177,543 | SEC↗ |
| DFPH Oncology Institute, Inc. | J Other deriv | 2021-11-12 | 2021-11-16 | 625,000 | — | $0 | 625,000 | SEC↗ |
| DFPH Oncology Institute, Inc. | C Conversion | 2021-11-12 | 2021-11-16 | 85,113 | — | $0 | 85,113 | SEC↗ |
| DFPH Oncology Institute, Inc. | C Conversion | 2021-11-12 | 2021-11-16 | 40 | — | $0 | 40 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | C Conversion deriv | 2021-10-26 | 2021-10-28 | 7,186,489 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | C Conversion deriv | 2021-10-26 | 2021-10-28 | 7,186,489 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | C Conversion | 2021-10-26 | 2021-10-28 | 756,472 | — | $0 | 756,472 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | C Conversion | 2021-10-26 | 2021-10-28 | 756,472 | — | $0 | 756,472 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | P Buy | 2021-10-26 | 2021-10-28 | 387,500 | $16.00 | $6.20M | 1,143,972 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | P Buy | 2021-10-26 | 2021-10-28 | 387,500 | $16.00 | $6.20M | 1,143,972 | SEC↗ |
| DALS DA32 Life Science Tech Acq | D To issuer deriv | 2021-08-05 | 2021-08-09 | 701,250 | — | $0 | 4,465,000 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 4,831,384 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 45,716,568 | — | $0 | 13,011,988 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 45,716,568 | — | $0 | 13,011,988 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 13,011,988 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 13,011,988 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 4,831,384 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 2,417,628 | — | $0 | 2,417,628 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 2,417,628 | — | $0 | 2,417,628 | SEC↗ |
| NUVL Nuvalent, Inc. | P Buy deriv | 2021-08-02 | 2021-08-04 | 300,000 | $17.00 | $5.10M | 2,717,628 | SEC↗ |
| NUVL Nuvalent, Inc. | P Buy deriv | 2021-08-02 | 2021-08-04 | 300,000 | $17.00 | $5.10M | 2,717,628 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion | 2021-08-02 | 2021-08-04 | 8,494,140 | — | $0 | 8,772,840 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion | 2021-08-02 | 2021-08-04 | 8,494,140 | — | $0 | 8,772,840 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion | 2021-08-02 | 2021-08-04 | 897,671 | — | $0 | 9,670,511 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion | 2021-08-02 | 2021-08-04 | 897,671 | — | $0 | 9,670,511 | SEC↗ |
| DALS DA32 Life Science Tech Acq | A Award | 2021-07-30 | 2021-08-03 | 650,000 | $10.00 | $6.50M | 2,250,000 | SEC↗ |
| DALS DA32 Life Science Tech Acq | P Buy | 2021-07-30 | 2021-08-03 | 1,600,000 | $10.00 | $16.00M | 1,600,000 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award deriv | 2021-07-28 | 2021-07-30 | 43,000 | — | $0 | 43,000 | SEC↗ |
| NUVL Nuvalent, Inc. | A Award deriv | 2021-07-28 | 2021-07-30 | 43,000 | — | $0 | 43,000 | SEC↗ |
| AFIB Acutus Medical, Inc. | P Buy | 2021-07-19 | 2021-07-21 | 390,836 | $14.00 | $5.47M | 1,974,638 | SEC↗ |
| AFIB Acutus Medical, Inc. | P Buy | 2021-07-19 | 2021-07-21 | 680,592 | $14.00 | $9.53M | 3,438,589 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2021-07-09 | 2021-07-13 | 99,325 | $15.81 | $1.57M | 0 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2021-07-07 | 2021-07-07 | 6,837 | $15.87 | $108.5K | 99,325 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2021-07-06 | 2021-07-07 | 49,239 | $16.20 | $797.7K | 106,162 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2021-07-02 | 2021-07-07 | 10,599 | $17.01 | $180.3K | 155,401 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2021-06-30 | 2021-07-02 | 228,571 | $8.75 | $2.00M | 1,943,423 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2021-06-30 | 2021-07-02 | 228,569 | $8.75 | $2.00M | 1,943,406 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2021-06-30 | 2021-07-02 | 228,570 | $8.75 | $2.00M | 1,943,420 | SEC↗ |
| AFIB Acutus Medical, Inc. | A Award deriv | 2021-06-17 | 2021-09-02 | 7,022 | — | $0 | 7,022 | SEC↗ |
| AFIB Acutus Medical, Inc. | A Award | 2021-06-17 | 2021-09-02 | 1,800 | — | $0 | 4,022 | SEC↗ |
| CMAX Deerfield Healthcare Techn | M Exercise deriv | 2021-06-08 | 2021-06-10 | 3,368,750 | — | $0 | 0 | SEC↗ |
| CMAX Deerfield Healthcare Techn | M Exercise deriv | 2021-06-08 | 2021-06-10 | 50,000 | — | $0 | 0 | SEC↗ |
| CMAX Deerfield Healthcare Techn | J Other deriv | 2021-06-08 | 2021-06-10 | 672,000 | — | $0 | 672,000 | SEC↗ |
| CMAX Deerfield Healthcare Techn | A Award deriv | 2021-06-08 | 2021-06-10 | 2,916,667 | — | $0 | 2,916,667 | SEC↗ |
| CMAX Deerfield Healthcare Techn | A Award | 2021-06-08 | 2021-06-10 | 9,600,000 | $10.00 | $96.00M | 12,960,000 | SEC↗ |
| CMAX Deerfield Healthcare Techn | A Award | 2021-06-08 | 2021-06-10 | 400,000 | $10.00 | $4.00M | 400,000 | SEC↗ |
| CMAX Deerfield Healthcare Techn | M Exercise | 2021-06-08 | 2021-06-10 | 3,368,750 | — | $0 | 3,768,750 | SEC↗ |
| CMAX Deerfield Healthcare Techn | M Exercise | 2021-06-08 | 2021-06-10 | 50,000 | — | $0 | 50,000 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion deriv | 2021-06-01 | 2021-06-03 | 0 | — | $0 | 0 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion deriv | 2021-06-01 | 2021-06-03 | 0 | — | $0 | 0 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion deriv | 2021-06-01 | 2021-06-03 | 6,457,723 | — | $0 | 0 | SEC↗ |
| OMIC Singular Genomics Systems, | P Buy | 2021-06-01 | 2021-06-03 | 450,000 | $22.00 | $9.90M | 7,484,871 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion | 2021-06-01 | 2021-06-03 | 577,148 | $17.60 | $10.16M | 577,148 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion | 2021-06-01 | 2021-06-03 | 577,148 | $17.60 | $10.16M | 7,034,871 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion | 2021-06-01 | 2021-06-03 | 6,457,723 | — | $0 | 6,457,723 | SEC↗ |
| OMIC Singular Genomics Systems, | P Buy | 2021-06-01 | 2021-06-03 | 1,050,000 | $22.00 | $23.10M | 1,627,148 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | A Award deriv | 2021-05-12 | 2021-05-17 | 8,300 | — | $0 | 8,300 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | C Conversion deriv | 2021-05-04 | 2021-05-04 | 15,195,094 | — | $0 | 0 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | P Buy | 2021-05-04 | 2021-05-04 | 800,000 | $16.00 | $12.80M | 2,552,787 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | C Conversion | 2021-05-04 | 2021-05-04 | 1,752,787 | — | $0 | 1,752,787 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-30 | 1,572,960 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-30 | 433,551 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-30 | 1,301,626 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2021-03-30 | 2021-03-30 | 625,000 | $16.00 | $10.00M | 3,933,137 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion | 2021-03-30 | 2021-03-30 | 1,301,626 | — | $0 | 2,874,586 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion | 2021-03-30 | 2021-03-30 | 1,572,960 | — | $0 | 1,572,960 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion | 2021-03-30 | 2021-03-30 | 433,551 | — | $0 | 3,308,137 | SEC↗ |
| ONCR Oncorus, Inc. | P Buy | 2021-02-17 | 2021-02-18 | 32,884 | $19.00 | $624.8K | 345,167 | SEC↗ |
| ONCR Oncorus, Inc. | P Buy | 2021-02-17 | 2021-02-18 | 133,558 | $19.00 | $2.54M | 1,401,905 | SEC↗ |
| ONCR Oncorus, Inc. | P Buy | 2021-02-17 | 2021-02-18 | 133,558 | $19.00 | $2.54M | 1,401,905 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | C Conversion deriv | 2021-02-09 | 2021-02-09 | 1,717,033 | — | $0 | 0 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | P Buy | 2021-02-09 | 2021-02-09 | 665,000 | $17.00 | $11.30M | 2,382,033 | SEC↗ |
| TERN Terns Pharmaceuticals, Inc | C Conversion | 2021-02-09 | 2021-02-09 | 1,717,033 | — | $0 | 1,717,033 | SEC↗ |
| LUMO LUMOS PHARMA, INC. | S Sale | 2021-01-08 | 2021-01-08 | 1,000 | $24.11 | $24.1K | 890,080 | SEC↗ |
| LUMO LUMOS PHARMA, INC. | S Sale | 2021-01-08 | 2021-01-08 | 101,600 | $22.24 | $2.26M | 784,568 | SEC↗ |
| LUMO LUMOS PHARMA, INC. | S Sale | 2021-01-08 | 2021-01-08 | 3,912 | $23.57 | $92.2K | 886,168 | SEC↗ |
| LUMO LUMOS PHARMA, INC. | S Sale | 2021-01-07 | 2021-01-08 | 4,378 | $25.05 | $109.7K | 891,080 | SEC↗ |
| LUMO LUMOS PHARMA, INC. | S Sale | 2021-01-07 | 2021-01-08 | 11,794 | $24.35 | $287.2K | 895,458 | SEC↗ |
| LUMO LUMOS PHARMA, INC. | S Sale | 2021-01-06 | 2021-01-08 | 931 | $22.64 | $21.1K | 907,252 | SEC↗ |
| LUMO LUMOS PHARMA, INC. | S Sale | 2021-01-06 | 2021-01-08 | 28,108 | $22.47 | $631.6K | 908,183 | SEC↗ |
| ONCR Oncorus, Inc. | C Conversion deriv | 2020-10-06 | 2020-10-08 | 2,449,761 | — | $0 | 0 | SEC↗ |
| ONCR Oncorus, Inc. | C Conversion deriv | 2020-10-06 | 2020-10-08 | 7,499,999 | — | $0 | 0 | SEC↗ |
| ONCR Oncorus, Inc. | C Conversion deriv | 2020-10-06 | 2020-10-08 | 7,499,999 | — | $0 | 0 | SEC↗ |
| ONCR Oncorus, Inc. | C Conversion deriv | 2020-10-06 | 2020-10-08 | 2,449,761 | — | $0 | 0 | SEC↗ |
| ONCR Oncorus, Inc. | C Conversion deriv | 2020-10-06 | 2020-10-08 | 2,449,761 | — | $0 | 0 | SEC↗ |
| ONCR Oncorus, Inc. | C Conversion | 2020-10-06 | 2020-10-08 | 202,670 | — | $0 | 823,150 | SEC↗ |
| ONCR Oncorus, Inc. | P Buy | 2020-10-06 | 2020-10-08 | 445,194 | $15.00 | $6.68M | 1,268,344 | SEC↗ |
| ONCR Oncorus, Inc. | P Buy | 2020-10-06 | 2020-10-08 | 445,194 | $15.00 | $6.68M | 1,268,344 | SEC↗ |
| ONCR Oncorus, Inc. | C Conversion | 2020-10-06 | 2020-10-08 | 202,670 | — | $0 | 202,670 | SEC↗ |
| ONCR Oncorus, Inc. | P Buy | 2020-10-06 | 2020-10-08 | 109,612 | $15.00 | $1.64M | 312,282 | SEC↗ |
| ONCR Oncorus, Inc. | C Conversion | 2020-10-06 | 2020-10-08 | 202,670 | — | $0 | 823,150 | SEC↗ |
| ONCR Oncorus, Inc. | C Conversion | 2020-10-06 | 2020-10-08 | 620,480 | — | $0 | 620,480 | SEC↗ |
| ONCR Oncorus, Inc. | C Conversion | 2020-10-06 | 2020-10-08 | 620,480 | — | $0 | 620,480 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | A Award deriv | 2020-09-29 | 2020-10-01 | 16,600 | — | $0 | 16,600 | SEC↗ |
| GRAY GRAYBUG VISION, INC. | C Conversion deriv | 2020-09-29 | 2020-10-01 | 2,624,901 | — | $0 | 0 | SEC↗ |
| GRAY GRAYBUG VISION, INC. | C Conversion deriv | 2020-09-29 | 2020-10-01 | 2,624,901 | — | $0 | 0 | SEC↗ |
| GRAY GRAYBUG VISION, INC. | C Conversion deriv | 2020-09-29 | 2020-10-01 | 12,809,912 | — | $0 | 0 | SEC↗ |
| GRAY GRAYBUG VISION, INC. | C Conversion deriv | 2020-09-29 | 2020-10-01 | 12,809,910 | — | $0 | 0 | SEC↗ |
| GRAY GRAYBUG VISION, INC. | C Conversion deriv | 2020-09-29 | 2020-10-01 | 2,624,901 | — | $0 | 0 | SEC↗ |
| GRAY GRAYBUG VISION, INC. | C Conversion | 2020-09-29 | 2020-10-01 | 291,467 | — | $0 | 291,467 | SEC↗ |
| GRAY GRAYBUG VISION, INC. | C Conversion | 2020-09-29 | 2020-10-01 | 291,467 | — | $0 | 1,713,873 | SEC↗ |
| GRAY GRAYBUG VISION, INC. | P Buy | 2020-09-29 | 2020-10-01 | 1,562,500 | $16.00 | $25.00M | 1,853,967 | SEC↗ |
| GRAY GRAYBUG VISION, INC. | C Conversion | 2020-09-29 | 2020-10-01 | 1,422,406 | — | $0 | 1,422,406 | SEC↗ |
| GRAY GRAYBUG VISION, INC. | C Conversion | 2020-09-29 | 2020-10-01 | 1,422,406 | — | $0 | 1,422,406 | SEC↗ |
| GRAY GRAYBUG VISION, INC. | C Conversion | 2020-09-29 | 2020-10-01 | 291,467 | — | $0 | 1,713,873 | SEC↗ |
| AFIB Acutus Medical, Inc. | C Conversion deriv | 2020-08-10 | 2020-08-12 | 449,992 | — | $0 | 0 | SEC↗ |
| AFIB Acutus Medical, Inc. | C Conversion deriv | 2020-08-10 | 2020-08-12 | 1,002,464 | — | $0 | 0 | SEC↗ |
| AFIB Acutus Medical, Inc. | C Conversion deriv | 2020-08-10 | 2020-08-12 | 189,366 | — | $0 | 0 | SEC↗ |
| AFIB Acutus Medical, Inc. | C Conversion deriv | 2020-08-10 | 2020-08-12 | 1,199,980 | — | $0 | 0 | SEC↗ |
| AFIB Acutus Medical, Inc. | C Conversion | 2020-08-10 | 2020-08-12 | 1,199,980 | — | $0 | 1,199,980 | SEC↗ |
| AFIB Acutus Medical, Inc. | P Buy | 2020-08-10 | 2020-08-12 | 944,444 | $18.00 | $17.00M | 1,583,802 | SEC↗ |
| AFIB Acutus Medical, Inc. | C Conversion | 2020-08-10 | 2020-08-12 | 1,002,464 | — | $0 | 2,202,444 | SEC↗ |